Physician profile
Daniel Guerra
NPI 1467535005
$1,301.01
in general payments reported to CMS, 2019-2025
17 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $43.77 · 2021: $219 · 2022: $105 · 2023: $96.83 · 2024: $421 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705 · Entertainment: $17.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.63 |
| Entertainment | $17.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $407.42 | 2022-2025 | Symplicity G3 |
| Boston Scientific Corporation | $268.86 | 2019-2022 | |
| Heartflow, INC. | $149.56 | 2024 | |
| Shockwave Medical, INC | $99.63 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $70.71 | 2019-2020 | |
| Opsens INC. | $62.81 | 2019-2023 | Optowire |
| Janssen Pharmaceuticals, INC | $47.11 | 2019-2023 | Xarelto |
| Amgen INC. | $42.04 | 2024 | Repatha |
| Penumbra, INC. | $35.57 | 2024 | Penumbra System, Ruby Coil |
| Cardiva Medical, INC. | $24.10 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Novartis Pharmaceuticals Corporation | $23.59 | 2025 | |
| Kestra Medical Technology Services, INC. | $19.85 | 2024 | Assure Wcd |
| Abbott Laboratories | $15.94 | 2023 | Diamondback Coronary |
| Cardiovascular Systems INC. | $14.24 | 2023 | Diamondback Coronary |
| Cook Medical LLC | $13.30 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.28 | 2024 | Lifevest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Guerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.